ArticleJAMA2023
Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.
Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data.Addiction (Abingdon, England) · 2025Trial
- Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff.Substance abuse treatment, prevention, and policy · 2025Trial
- Addiction recovery is more than abstinence-our metrics should be too.Lancet regional health. Americas · 2026Article
- Trends in Buprenorphine and Methadone Dispensing Among Medicare Advantage and Commercial Enrollees, 2019-2024.AJPM focus · 2026Article
- Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: Multistate Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- Development and Testing of a Peer Recovery Support Services Intervention for Retention on Medications for Opioid Use Disorder.Journal of addiction medicine · 2026Article
- High-Deductible Health Plan Enrollment and Buprenorphine Dispensing.JAMA network open · 2026Article
- Impact of study design decisions on identification of treatment initiators of medications for opioid use disorder.Addiction (Abingdon, England) · 2026Article
- Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era.Addictive behaviors · 2026Article
- Evaluating the optimal duration of medication treatment for opioid use disorder.Addiction (Abingdon, England) · 2026Article
- State Prior Authorization Prohibitions and Buprenorphine Retention Among Privately Insured Patients.JAMA health forum · 2026Article
- Low-threshold Buprenorphine: Proposing the Ideal Service Model to Engage People With Severe Opioid Use Disorder.Journal of addiction medicine · 2026Article
- Self-Reported History of Precipitated Withdrawal: A Cross-Sectional Study of People Who Use Unregulated Opioids.Journal of addiction medicine · 2026Article
- Trends in Use of Medications for Opioid Use Disorder among Commercially Insured U.S. Surgical Patients, 2016 to 2022.Anesthesiology · 2026Article
- Treatment outcomes of an integrated treatment model for patients with co-occurring opioid use and schizophrenia spectrum disorders.Frontiers in psychiatry · 2026Article
- Real-world management of opioid use disorder in primary care 2015-2019: associations between clinical practice attributes, diagnosis, and treatment.Critical public health · 2026Article
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- Treatment Initiation and Outcomes Associated With Receipt of Emergency Department-Based Peer Support Following Opioid Overdose.Annals of emergency medicine · 2025Article
- A Measurement Science Framework to Optimize CDS for Opioid Use Disorder Treatment in the ED.Applied clinical informatics · 2025Article
- Duration of Methadone and Buprenorphine-Naloxone Treatment.JAMA network open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.